B. Riley Brokers Increase Earnings Estimates for Altimmune

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Stock analysts at B. Riley raised their FY2025 EPS estimates for shares of Altimmune in a research report issued on Friday, February 28th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of $0.86 for the year, up from their previous estimate of $0.73. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share.

ALT has been the subject of a number of other reports. Stifel Nicolaus started coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a "buy" rating and a $18.00 target price for the company. UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a "buy" rating and a $26.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Monday. Finally, William Blair started coverage on shares of Altimmune in a research report on Friday. They set a "market perform" rating for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $20.83.

Altimmune Stock Down 9.9 %

Altimmune stock opened at $5.99 on Monday. Altimmune has a twelve month low of $5.28 and a twelve month high of $12.35. The firm has a 50 day moving average price of $6.81 and a 200-day moving average price of $7.20. The company has a market capitalization of $426.04 million, a P/E ratio of -3.86 and a beta of 0.19.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ALT. Ameriprise Financial Inc. boosted its holdings in Altimmune by 35.6% in the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock valued at $37,888,000 after purchasing an additional 1,378,854 shares during the period. Geode Capital Management LLC boosted its holdings in Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock valued at $10,244,000 after purchasing an additional 74,194 shares during the period. Bellevue Group AG boosted its holdings in Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company's stock valued at $6,817,000 after purchasing an additional 81,786 shares during the period. Northern Trust Corp boosted its holdings in Altimmune by 5.7% in the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company's stock valued at $4,801,000 after purchasing an additional 35,918 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in Altimmune by 33.2% in the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company's stock valued at $4,364,000 after purchasing an additional 151,001 shares during the period. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.